
News|Videos|November 14, 2023
LIBRETTO-431: 1L Selpercatinib in RET Fusion–Positive Advanced NSCLC
Author(s)Rohit Gosain, MD, Rahul Gosain, MD
Alexander Spira, MD, PhD, FACP, joins the Oncology Brothers in reviewing data from LIBRETTO-431 and frontline selpercatinib in patients with RET fusion–positive advanced non–small cell lung cancer.
Episodes in this series






































